Repression of miR-135b-5p promotes metastasis of early-stage breast cancer by regulating downstream target SDCBP
- PMID: 31024042
- DOI: 10.1038/s41374-019-0258-1
Repression of miR-135b-5p promotes metastasis of early-stage breast cancer by regulating downstream target SDCBP
Abstract
Metastasis is an essential event for breast cancer (BC) progression even after initial surgery. The identification of patients with a high probability of metastasis at an early stage is particularly important in clinical practice and requires individualized treatment or early prevention. A retrospective study of 242 cases of ductal carcinoma in situ with microinvasion (DCIS-Mi), the first stage of invasive BC, was performed in this follow-up analysis. Of all patients, 8 developed metastases, and they were all included for further mechanistic studies with control group of 24 DCIS-Mi by matched-pair designing. By screening DCIS-Mi with different prognoses, we found that the DCIS-Mi that metastasized had significantly lower miR-135b-5p expression than the DCIS-Mi that did not. The function of miR-135b-5p was studied in vitro and in vivo invasion and metastasis assays. We also validated a novel target gene for miR-135b-5p, syndecan binding protein (SDCBP), and assessed the functional consequences of SDCBP by invasion assays. By checking different BC cell lines, a strong inverse correlation between miR-135b-5p and SDCBP expression was recorded. For the functional study, the inhibition of miR-135b-5p was accompanied by increased BC cell growth, epithelial-mesenchymal transition (EMT), migration and invasion in vitro. Interestingly, silencing SDCBP can reverse miR-135b-5p-dependent EMT and proliferation. In vivo studies demonstrated that the newly revealed miR-135b-5p/SDCBP axis increased cell proliferation, invasion and malignant transformation, as well as promoted metastasis in a xenograft tumor mouse model. Thus, our clinical patient cohort and functional data suggest that miR-135b-5p/SDCBP is a crucial determinant of BC metastasis at a very early stage. Our results may shed light on the importance of miR-135b-5p molecular diagnosis and prognosis, as well as the early prevention of BC for metastasis.
Similar articles
-
Dynamically decreased miR-671-5p expression is associated with oncogenic transformation and radiochemoresistance in breast cancer.Breast Cancer Res. 2019 Aug 7;21(1):89. doi: 10.1186/s13058-019-1173-5. Breast Cancer Res. 2019. PMID: 31391072 Free PMC article.
-
miR-135b-5p Promotes migration, invasion and EMT of pancreatic cancer cells by targeting NR3C2.Biomed Pharmacother. 2017 Dec;96:1341-1348. doi: 10.1016/j.biopha.2017.11.074. Epub 2017 Nov 28. Biomed Pharmacother. 2017. PMID: 29196101
-
miR-216b suppresses breast cancer growth and metastasis by targeting SDCBP.Biochem Biophys Res Commun. 2017 Jan 1;482(1):126-133. doi: 10.1016/j.bbrc.2016.10.003. Epub 2016 Oct 5. Biochem Biophys Res Commun. 2017. PMID: 27720715
-
MicroRNA-135b mainly functions as an oncogene during tumor progression.Pathol Res Pract. 2024 Oct;262:155547. doi: 10.1016/j.prp.2024.155547. Epub 2024 Aug 15. Pathol Res Pract. 2024. PMID: 39151250 Review.
-
MDA-9/Syntenin (SDCBP): Novel gene and therapeutic target for cancer metastasis.Pharmacol Res. 2020 May;155:104695. doi: 10.1016/j.phrs.2020.104695. Epub 2020 Feb 13. Pharmacol Res. 2020. PMID: 32061839 Free PMC article. Review.
Cited by
-
Revisiting the Syndecans: Master Signaling Regulators with Prognostic and Targetable Therapeutic Values in Breast Carcinoma.Cancers (Basel). 2023 Mar 16;15(6):1794. doi: 10.3390/cancers15061794. Cancers (Basel). 2023. PMID: 36980680 Free PMC article. Review.
-
Human microRNA similarity in breast cancer.Biosci Rep. 2021 Oct 29;41(10):BSR20211123. doi: 10.1042/BSR20211123. Biosci Rep. 2021. PMID: 34612484 Free PMC article.
-
LncRNA GAPLINC Promotes Renal Cell Cancer Tumorigenesis by Targeting the miR-135b-5p/CSF1 Axis.Front Oncol. 2021 Oct 14;11:718532. doi: 10.3389/fonc.2021.718532. eCollection 2021. Front Oncol. 2021. PMID: 34722262 Free PMC article.
-
miR‑135b‑5p enhances the sensitivity of HER‑2 positive breast cancer to trastuzumab via binding to cyclin D2.Int J Mol Med. 2020 Oct;46(4):1514-1524. doi: 10.3892/ijmm.2020.4681. Epub 2020 Jul 22. Int J Mol Med. 2020. PMID: 32700749 Free PMC article.
-
The Role and Therapeutic Value of Syndecan-1 in Cancer Metastasis and Drug Resistance.Front Cell Dev Biol. 2022 Jan 18;9:784983. doi: 10.3389/fcell.2021.784983. eCollection 2021. Front Cell Dev Biol. 2022. PMID: 35118073 Free PMC article. Review.
References
-
- Bianchi S, Vezzosi V. Microinvaive carcinoma of the breast. Pathol Oncol Res. 2008;14:105–11. - DOI
-
- Wang L, Zhang W, Lyu S, Liu X, Zhang T, Liu S, et al. Clinicopathologic characteristics and molecular subtypes of microinvasive carcinoma of the breast. Tumour Biol. 2015;36:2241–8. - DOI
-
- Fan L, Zheng Y, Yu KD, Liu GY, Wu J, Lu JS, et al. Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, China. Breast Cancer Res Treat. 2009;117:409–16. - DOI
-
- Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4. - DOI
-
- Parikh RR, Haffty BG, Lannin D, Moran MS. Ductal carcinoma in situ with microinvasion: prognostic implications, long-term outcomes, and role of axillary evaluation. Int J Radiat Oncol Biol Phys. 2012;82:7–13. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical